ALSO READPfizer, Astellas prostate cancer drug succeeds key trial Pfizer, Roche and Aspen face South Africa probe over cancer drug prices Pfizer revenue misses as demand falls for older drugs, Prevnar EXCLUSIVE: Advent pulls bid for Pfizer's Brazil venture - sources EXCLUSIVE :Advent pulls bid for Pfizer's Brazil venture - sources
(Corrects second paragraph to show that Xtandi second-quarter sales were for Pfizer in the United States, not global overall sales)
By Divya Grover
The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body - and raked in U.S. sales of $141 million in the second quarter for Pfizer.
An approval to treat non-metastatic CRPC would significantly boost sales of Xtandi, which Pfizer got access to when it bought Medivation for $14 billion last year. Astellas owns the rights to sell Xtandi outside the United States.
Pfizer said on Thursday that Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival rate in men with non-metastatic CRPC without their cancer spreading, when compared with the standalone anti-hormone therapy.
Patients with CRPC experience cancer progression despite androgen deprivation therapy, a treatment that blocks the production of the hormone.
Earlier this month, the U.S. Food and Drug Administration approved Pfizer's Mylotarg for certain patients with acute myeloid leukemia, re-clearing a drug that had been pulled off the market in 2010.
Pfizer's shares rose 1.4 percent to $35.55 in light premarket trading.
(Reporting by Divya Grover and Tamara Mathias in Bengaluru; Editing by Savio D'Souza and Saumyadeb Chakrabarty)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)